Generation Bio (GBIO) Stock Analysis

What Generation Bio does

Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.

Key metrics

ETFs linked to GBIO

Broad-market and Healthcare sector ETFs an investor holding Generation Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GBIO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Generation Bio?

Generation Bio trades under the ticker GBIO on NASDAQ.

Which exchange is GBIO listed on?

GBIO is listed on NASDAQ.

What sector does Generation Bio operate in?

Generation Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GBIO in a portfolio?

PortView shows GBIO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.